The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Slayback Pharma LLC
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Azurity Pharmaceuticals, a pharmaceutical company specializing in the provision of innovative medicines to overlooked patients, on the acquisition of Slayback Pharma LLC ("Slayback"), a company focused on complex generic and specialty pharmaceutical products
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
GI Alliance
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advising the management and majority physician owners of GI Alliance, the largest gastroenterology practice in the United States, on its recapitalization and buyout of minority partner, Waud Capital
![USA/UK U.S.A., U.K. flags](https://www.greenhill.com/sites/default/files/usa_uk.gif)
Acacia Pharma Group plc
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
US Acute Care Solutions
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advising US Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on its recapitalization and buyout of minority partner, Welsh Carson
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Akorn, Inc.
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised Ad Hoc Group of First Lien Term Loan Lenders on Akorn’s in-court recapitalization
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Concordia International Corp.
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt
![South Africa/Switzerland South Africa, Switzerland flags](https://www.greenhill.com/sites/default/files/s-africa_switz_91006.gif)
Hirslanden Private Hospital Group
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt
![USA/UK U.S.A., U.K. flags](https://www.greenhill.com/sites/default/files/usa_uk.gif)
US rights to Toprol-XL (AstraZeneca)
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Bionomics Limited
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.
![Brazil Brazil flag](https://www.greenhill.com/sites/default/files/brazil.gif)
Recepta Biopharma
![Brazil Brazil flag](https://www.greenhill.com/sites/default/files/brazil.gif)
Advised Recepta Biopharma on a capital raise
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Refinancing of syndicated bank debt facilities
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Advised Primary Health Care on the refinancing of its A$1.25 billion syndicated bank debt facilities
![South Africa/Switzerland South Africa, Switzerland flags](https://www.greenhill.com/sites/default/files/s-africa_switz_91006.gif)
Mediclinic International Limited
Advised Mediclinic International, South Africa’s second largest and Switzerland’s largest provider of private hospital services, on the restructuring of its entire balance sheet, including $2.2 billion debt refinancing in Switzerland and a $0.6 billion rights issue in South Africa
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
ISTA Pharmaceuticals, Inc.
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its defense against an unsolicited offer from Valeant Pharmaceuticals and on its review of strategic alternatives
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Bionomics Ltd
Advised Bionomics Ltd, in relation to the tender process run by Bionomics’ largest shareholder, Start-up Australia Ventures (“Start-up”), for its 28% stake in the company, follow on sell-down of Start-up’s stake to 8% and associated capital raising by Bionomics
![USA/Switzerland U.S.A., Swiss flags](https://www.greenhill.com/sites/default/files/usa_swiss.gif)
Alcon, Inc.
![Switzerland Switzerland flag](https://www.greenhill.com/sites/default/files/switzerland.gif)
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company